LR19122 / LG Chem - LARVOL DELTA

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series (clinicaltrials.gov) - P2/3 | N=1186 | Recruiting | Sponsor: LG Chem | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatitis B • Infectious Disease • Inflammation • Influenza • Pertussis • Respiratory Diseases • Tetanus

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series (clinicaltrials.gov) - P2/3 | N=1186 | Not yet recruiting | Sponsor: LG Chem

New P2/3 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Influenza • Pertussis • Respiratory Diseases • Tetanus

Study to Evaluate the Immunogenicity and Safety of LBVD (Hexavalent Vaccine; DTwP-HepB-IPV-Hib Vaccine), Given to Healthy Infants at Primary Series (clinicaltrials.gov) - P2/3 | N=1438 | Not yet recruiting | Sponsor: LG Chem

New P2/3 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pertussis • Respiratory Diseases • Tetanus